Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet

Nomura/Instinet raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $156.00 (from $148.00) while maintaining a Buy rating.

Analyst Christopher Marai commented, "Alexion reported results from the P3 301 study of ALXN1210 in PNH-naïve patients. The study demonstrated non-inferiority across all co-primary and four key... More

Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird

Baird raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160.00 (from $150.00) while maintaining a Outperform rating.

Analyst Michael E. Ulz commented, "Following the call, we remain encouraged by the Phase 3 PNH naïve results with ALXN1210 demonstrating non-inferiority on all six key endpoints with... More

Alexion Pharmaceuticals (ALXN) PT Raised to $151 at Raymond James

Raymond James raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $151.00 (from $134.00) while maintaining an Outperform rating following data today.

RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results

RBC Capital analsyt Kennen MacKay was positive on Alexion Pharma (NASDAQ: ALXN) after ALXN-1210 hit its hurdle in the 1st of 2 Phase 3 trials.

MacKay called the results a "win, but note a full re-rate scenario." He sees a 10-15% move.

JPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results

JPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results from the PNH naïve phase 3 study of ALXN1210 versus Soliris.

Analyst Anupam Rama believes that the data is "a clear win for ALXN1210 in... More

Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMO

BMO Capital analyst M. Ian Somaiya expects shares of Alexion Pharmaceuticals (NASDAQ: ALXN) trade higher as investors breathe a sigh of relief following release of Phase 3 ALXN-1210 data.

"The treatment naïve study met most investor expectations, meeting the non-inferiority primary endpoint (some... More